Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Terpenes from cannabis may relieve chronic pain without THC’s psychoactive effects. Researchers found that certain terpenes ...
Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...
The end of compounded versions of weight-loss drugs is near, leaving patients scrambling for alternatives. Some “copycat” ...
On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...
The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...